biostudies-literatureUnknown6(3)Kim WSRegeneron PharmaceuticalsThe phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of resNature cancer528-539https://www.ebi.ac.uk/biostudies/studies/S-EPMC12003196biostudies-literatureOdronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.PMC12003196Rossi FCunningham DZhang HPoon LMZhang MCarpio CMiqueleiz SZhang QVenugopal PKe XKim WSUchida TMagnano LAlonso AJin JWrobel TChong GGutierrez AKuroda JHe PThieblemont COgawa YOng SYELM-2 InvestigatorsHsieh WSRok Do YFlenghi LJimenez-Ubieto AGonzalez-Barca ELech-Maranda EBouabdballah KCao JWu SJCoello APFarooq UYi STaszner MWei ZShariff SSkert CBai ODamaj GLArnason JChu MBachy EIbrahimi SJandl TOh SYEom HSNakamae HYoshida IPrince HMQian WZhu JKlein AUfkin MJo TKuhnl AJagadeesh DKim TMKnopinska-Posluszny WLuminari SHuang HAmbati STobai TTsukasaki KChen TYTan TDVillasboas JCJo JCBrouwer-Visser JKim BSKeating MMBattistini RLa Rosee PGChen YElmusharaf NCapochiani EAyyappan SCordoba RMinami YLi CLi DTakeuchi MVaidya RYamamoto RKim JSDelwail VIskierka-Jazdzewska EWang MCGao LRobak TLewis DChaudhry ANagai HZou LTucker DJarque ICai JWalewski JAndreu RMun YCAwan FZilioli VTani MGanju VBagnato LYuda JSong YYeh SPMorschhauser FYamauchi NRose HCho SGHaioun CMohamed HDuell JMartin AStevens DIshizawa KLeslie LLim FHebart HAllan JWeber TSuehiro YChoquet SZinzani PLTessoulin BBrociner MGaidano GfalseOdronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of res2025-01-01T00:00:00Z2025 Mar2026-06-01T14:48:58.47Z2026-04-08T13:31:08.217ZS-EPMC120031964009765710.1038/s43018-025-00921-6